Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Location status: Recruiting
Location contact
Kang Associate chief physician
CONTACT
NCT Number: NCT06353126
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery.
The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS);2) Pathological response rate (Pathological Response); 3) Proportion of patients completing living donor liver transplantation; 4) Adverse events related to DEB-TACE.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Phase 4
Shanghai, China
Location status: Recruiting
Kang Associate chief physician
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).
During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells.
Time frame: 2 years
the time from DEB-TACE treatment until tumor recurrence in the original site, transplanted liver, other tissues and organs, or death, whichever occurs first.
Time frame: 5 years
the time from DEB-TACE treatment until death from any cause.
Time frame: 1 year
at the time of the surgery
Time frame: at the time of the surgery
1 year
Time frame: from DEB-TACE to the surgery
2 weeks
Contact information is provided by the study sponsor or research team.
RenJi Hospital
Other
A Prospective, Single Arm, Exploratory Study of Using Drug-eluting Beads Transarterial Chemoembolization Prior to Liver Transplantation in the Treatment of Hepatocellular Carcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00034216
Breast Cancer, Breast Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07124000
Adenocarcinoma, Adenocarcinoma (NOS)
Birmingham, Alabama, United States
View Trial DetailsNCT05492136
Cancer, Treatment-Related, Digestive System Diseases
Barcelona, Spain
View Trial DetailsNCT07717437
Adenocarcinoma, Carcinoma
Chicago, Illinois, United States
View Trial Details